Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreren
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

FRESH TRACKS THERAPEUTICS, INC.

(FRTX)
  Rapport
Vertraagde tijd Nasdaq  -  21:54:05 07-02-2023
2.360 USD   -2.88%
27/01Fresh Tracks Therapeutics, Inc. Kondigt wijzigingen in de leiding aan, met ingang van 1 februari 2023
CI
11/01Fresh Tracks Therapeutics, Inc. Kondigt publicatie aan van preklinische gegevens voor FRTX-02
CI
2022Fresh Tracks Therapeutics, Inc. : Oppenheimer handhaaft koopadvies
MM
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Nieuws in andere talen op FRESH TRACKS THERAPEUTICS, INC.
07/02Fresh Tracks Therapeutics, Inc. : Change in Directors or Principal Officers, Financial Sta..
02/02Fresh Tracks Therapeutics : Company Overview Presentation
27/01Fresh Tracks Therapeutics, Inc. : Change in Directors or Principal Officers, Regulation FD..
27/01Fresh Tracks Therapeutics Names Andrew Sklawer CEO
27/01Fresh Tracks Therapeutics Appoints Andrew Sklawer as Chief Executive Officer
27/01Fresh Tracks Therapeutics, Inc. Announces Executive Changes, Effective February 1, 2023
12/01Fresh Tracks Therapeutics Announces Publication of Preclinical Data for FRTX-02, a Pote..
12/01Fresh Tracks Therapeutics Announces Publication of Preclinical Data for FRTX-02, a Pote..
11/01Fresh Tracks Therapeutics Announces Publication of Preclinical Data for FRTX-02, a Pote..
11/01Fresh Tracks Therapeutics, Inc. Announces Publication of Preclinical Data for FRTX-02
04/01Fresh Tracks Therapeutics : Company Overview Presentation
2022FRESH TRACKS THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
2022Fresh Tracks Therapeutics : Q3 Earnings Snapshot
2022Earnings Flash (BBI) FRESH TRACKS THERAPEUTICS Posts Q3 Revenue $0.5M
2022Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine..
2022Fresh Tracks Therapeutics Reports Third Quarter 2022†Financial Results and Provides Cor..
2022Fresh Tracks Therapeutics to Report Third Quarter 2022 Financial Results and Provide a ..
2022Fresh Tracks Therapeutics, Inc. : Change in Directors or Principal Officers, Financial Sta..
2022Fresh Tracks Therapeutics Appoints Deepak Chadha to the Additional Position of Chief Op..
2022Fresh Tracks Therapeutics Begins Multiple Ascending Dose Portion of Inflammatory Diseas..
2022Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of..
2022Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of..
2022Fresh Tracks Therapeutics, Inc. : Amendments to Articles of Inc. or Bylaws; Change in Fisc..
2022Brickell Biotech, Inc. has Changed its Name to Fresh Tracks Therapeutics, Inc
2022Brickell Biotech, Inc. will Change its Name to Fresh Tracks Therapeutics, Inc
2022Brickell Biotech Changes Name to Fresh Tracks Therapeutics
2022Brickell Biotech Announces Corporate Rebranding to Fresh Tracks Therapeutics
2022Fresh Tracks Therapeutics : Company Overview Presentation
2022Updates to Management's Discussion and Analysis of Financial Condition and Results of O..
2022Brickell Biotech, Inc. : Non-Reliance on Previous Financials, Audits or Interim Review (fo..
2022Brickell Biotech, Inc. : Notice of Delisting or Failure to Satisfy a Continued Listing Rul..
2022BRICKELL BIOTECH, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND..
2022Brickell : Q2 Earnings Snapshot
2022Brickell Biotech : Reports Second Quarter 2022 Financial Results and Provides Corporate Up..
2022Brickell Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months E..
2022Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate U..
2022Brickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporat..
2022Brickell Biotech, Inc. : Change in Directors or Principal Officers, Amendments to Articles..
2022Brickell Biotech, Inc. Announces Resignation of Dennison T. Veru from the Board of Dire..
2022Brickell Biotech Regains Compliance With Nasdaq's Minimum Bid Price Requirement for Con..
2022Brickell Biotech : Regains Compliance with Nasdaq Minimum Bid Price Requirement - Form 8-K
2022Brickell Biotech, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
2022Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement
2022Brickell Biotech to Participate at William Blair Biotech Focus Conference 2022
2022Brickell Biotech : Announces 1-For-45 Reverse Stock Split - Form 8-K
2022Brickell Biotech, Inc. : Material Modification to Rights of Security Holders, Amendments t..
2022Brickell Biotech Announces 1-For-45 Reverse Stock Split
2022Brickell Biotech : Delisting/Failure to Satisfy Listing Rule/Transfer of Listing - Form 8-..
2022Brickell Biotech, Inc. : Notice of Delisting or Failure to Satisfy a Continued Listing Rul..
2022Brickell Biotech Chief Accounting Officer Resigns; Successor Named
2022Brickell Biotech, Inc. : Change in Directors or Principal Officers, Financial Statements a..
2022Brickell Biotech, Inc. Announces Executive Changes
2022Brickell Biotech, Inc. : Entry into a Material Definitive Agreement, Unregistered Sale of ..
2022Brickell Biotech Begins Dosing in Phase 1 Trial of Atopic Dermatitis Treatment
2022Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02
2022Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02
2022Brickell Biotech, Inc. : Change in Directors or Principal Officers, Submission of Matters ..
2022North American Morning Briefing: Stock Futures -3-
2022Brickell : Q1 Earnings Snapshot
2022BRICKELL BIOTECH, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND..
2022Brickell Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2..
2022Earnings Flash (BBI) BRICKELL BIOTECH Posts Q1 Revenue $92,000
2022Brickell Biotech Reports First Quarter 2022†Financial Results and Provides Corporate Up..
2022Brickell Biotech to Report First Quarter 2022 Financial Results and Provide a Corporate..
2022Wall Street Set for Higher Open Ahead of Fed Funds Rate Announcement, ISM's Services In..
2022Top Premarket Gainers
2022Botanix Pharmaceuticals Acquires Assets for Excessive Underarm Sweating Treatment
2022Brickell Biotech, Inc. : Submission of Matters to a Vote of Security Holders, Regulation F..
2022Brickell Biotech, Inc. : Entry into a Material Definitive Agreement, Termination of a Mate..
2022Brickell Biotech Announces Sale of Sofpironium Bromide to Botanix Pharmaceuticals
2022Brickell Biotech Announces Adjournment of Annual Meeting of Stockholders
2022BRICKELL BIOTECH, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND..
2022Brickell : Q4 Earnings Snapshot
2022Brickell Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 20..
2022Brickell Biotech : Reports Fourth Quarter and Full Year 2021 Financial Results and Provide..
2022Earnings Flash (BBI) BRICKELL BIOTECH Reports Q4 Revenue $104,000, vs. Street Est of $0..
2022Brickell Biotech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 3..
2022Brickell Biotech Reports Fourth Quarter and Full Year 2021†Financial Results and Provid..
2022Brickell Biotech Selected for a Late-Breaking Oral Presentation of US Phase 3 Pivotal C..
2022Brickell Biotech to Report Fourth Quarter and Full Year 2021 Financial Results and Prov..
2022Brickell Biotech Obtains Exclusive Rights to Carna Biosciences' Inhibitor Portfolio Tar..
2022Brickell Biotech : Acquires Exclusive Global Rights to Portfolio of Novel STING Inhibitors..
2022Brickell Biotech, Inc. : Entry into a Material Definitive Agreement (form 8-K)
2022Brickell Biotech, Inc. Enters into an Exclusive License Agreement with Carna Bioscience..
2022Brickell Biotech Acquires Exclusive Global Rights to Portfolio of Novel STING Inhibitor..
2022Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ..
2022Top Midday Gainers
2022Top Premarket Gainers
2021Brickell Biotech, Inc. : Notice of Delisting or Failure to Satisfy a Continued Listing Rul..
2021Brickell : Q3 Earnings Snapshot
2021BRICKELL BIOTECH, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND..
2021Earnings Flash (BBI) BRICKELL BIOTECH Reports Q3 Revenue $0.1M, vs. Street Est of $0.15..
2021Brickell Biotech Reports Third Quarter 2021 Financial Results and Provides Corporate Up..
2021Brickell Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months E..
2021Brickell Biotech, Inc. : Results of Operations and Financial Condition (form 8-K)
2021Brickell Biotech, Inc. Expands Leadership Team by Appointing Dr. Monica Luchi as Chief ..
2021Brickell Biotech Reports Third Quarter 2021 Financial Results and Provides Corporate Up..
2021Brickell Biotech Announces Proposed Underwritten Public Offering of Common Stock - Form..
2021Brickell Biotech, Inc. : Entry into a Material Definitive Agreement (form 8-K)
2021Brickell Biotech to Report Third Quarter 2021 Financial Results and Provide a Corporate..
Volgende evenement op FRESH TRACKS THERAPEUTICS, INC.